

In vitro activity of *Erythrophleum ivorense* extract against the promastigote stage of cutaneous *Leishmania* parasite, a member of *Leishmania (Mundinia) enriettii* complex isolates from Ghana

Alberta Serwah Anning¹, Godwin Kwakye-Nuako¹, Elvis Ofori Ameyaw¹, Mba-Tihssommah Mosore^{2,3} and Kwame Kumi Asare^{1,4,*}

Abstract

Background. Cutaneous leishmaniasis causes physical disfigurement and impairment on affected individuals, however, little attention has been paid to its eradication. The situation of this neglected disease is complicated with the expansion of the non-human pathogenic *Leishmania enriettii* complex causing infection in humans. We have previously shown that the extract from *Erythrophleum ivorense* has leishmanicidal activity against promastigote stages of the *L. enriettii* complex isolate from Ghana and *Leishmania donovani*. The extract of *E. ivorense* has shown to have anti-inflammatory, wound-healing ability, antiallergic, antimalarial and antischistosomal activity. However, the concentration threshold of *E. ivorense* extract required for leishmanicidal activity against the emerging human pathogenic *L. enriettii* complex isolates is not clear.

Aim. To test for the concentration threshold of *E. ivorense* extract required to obtain ideal leishmanicidal activity against the promastigote stage of human pathogenic *L. enriettii* complex isolates from Ghana.

Method. The ethanolic leaf extract of *E. ivorense* was serially diluted and tested against the promastigote stage of the *L. enriettii* complex. Parasite inhibition was measured at 590 nm using a spectrophotometer after staining parasites with trypan blue. To select the threshold concentration for maximum inhibition of the promastigote stage of the *L. enriettii* complex, the concentration cut-off statistic was used.

Results. The MIC of *E. ivorense* extract for *L. enriettii* promastigote inhibition was 62.3 µg ml⁻¹. The highest promastigote inhibition was observed at 72 h.

Conclusion. We show that a MIC of 62.3 µg ml⁻¹ of *E. ivorense* leaf extract exhibits an ideal leishmanicidal activity against the promastigote stage of *L. enriettii* complex isolates.

INTRODUCTION

The therapeutic value of medicinal plants cannot be over-emphasized [1]. Therapeutic activities of medicinal plants against infection-causing pathogens and immune-mediated diseases are widely known [2–4]. *Cinchona officinalis* and *Artemisia annua* medicinal plants that produce quinine and artemisinin, respectively, are currently the most effective

antiplasmodial drugs [5, 6]. Similarly, the extracts from aerial parts of *Erythrophleum ivorense* have shown to pharmacologically contain antiallergic, antioxidant, antihypertension, antitumour, anti-inflammatory, antiviral, hypo-lipidemic, antiarrhythmic, antimalarial and anticancer properties [7, 8]. The leaf extracts of *E. ivorense* have been reported to also have antischistosomal activity [9]. *E. ivorense* is a major medicinal

Received 10 June 2019; Accepted 25 July 2019; Published 03 September 2019

Author affiliations: ¹Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana; ²U. S. Naval Medical Research Unit No. 3 (NAMRU-3), Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana; ³Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, Ghana; ⁴Department of Protozoology Institute of Tropical Medicine (NEKKEN), Nagasaki University Sakamoto 1-12-4, Nagasaki 852-8523, Japan.

*Correspondence: Kwame Kumi Asare, kwamsare@hotmail.com

Keywords: Cutaneous leishmaniasis; *Leishmania enriettii* complex; leishmanicidal; *Erythrophleum ivorense*; promastigotes stage; Ghana.

Abbreviations: BME, basal medium Eagle; CCL2, chemokine (C-C motif) ligand 2; CL, cutaneous leishmaniasis; CXCL-9, chemokine (C-X-C motif) ligand 9; CXCL-10, chemokine (C-X-C motif) ligand 10; DMSO, dimethyl sulfoxide; FBS, foetal bovine serum; IFNγ, interferon gamma; IL-12, interleukin 12; LCL, lower control limit; MIC, minimum inhibitory concentration; PKDL, post kala-azar dermal leishmaniasis; ROC, receiver operating curve; TNT-α, tumour necrosis factor alpha; UCL, upper control limit.

000050 © 2019 The Authors

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Table 1. The sensitivity and specificity of the concentration cutoffs of the *E. ivorensis* leaf extract on *L. enriettii* promastigote inhibition.

Conc. cut off ($\mu\text{g ml}^{-1}$)	% sensitivity (95% CI)	% specificity (95% CI)	Likelihood ratio
15.00	100.0 (54.07–100.0)	16.67 (0.4211–64.12)	1.200
30.50	83.33 (35.88–99.58)	16.67 (0.4211–64.12)	1.000
44.50	83.33 (35.88–99.58)	33.33 (4.327–77.72)	1.250
53.00	66.67 (22.28–95.67)	33.33 (4.327–77.72)	1.000
64.50	66.67 (22.28–95.6)	50.00 (11.81–88.19)	1.333
82.50	50.00 (11.81–88.19)	50.00 (11.81–88.19)	1.000
99.00	50.00 (11.81–88.19)	66.67 (22.28–95.6)	1.500
108.0	33.33 (4.327–77.72)	66.67 (22.28–95.6)	1.000
133.5	33.33 (4.327–77.72)	83.33 (35.88–99.58)	2.000
166.5	33.33 (4.327–77.72)	100.0 (54.07–100.0)	
215.5	16.67 (0.4211–64.12)	100.0 (54.07–100.0)	

CI, confidence interval.

plant for the treatment of smallpox, inflammation, wound healing and convulsion in Ghana [10, 11] and with other several medicinal uses throughout Africa [12]. Recently, we showed that leaf extract of *E. ivorensis* has high cytotoxicity against the promastigote stage of cutaneous *Leishmania* species, *L. enriettii* complex isolates from Ghana [12, 13].

Leishmaniasis remains one of the most neglected diseases caused by kinetoplastid protozoan *Leishmania* [14, 15]. Leishmaniasis is a spectrum of diseases that presents as cutaneous, mucocutaneous and visceral forms that infect a wide range of specific hosts [16, 17]. Nearly 4 million new cases of leishmaniasis occur every year with about 70000 related deaths [18]. The expansion and cross-host infections by zoonotic *Leishmania* species is a cause of concern to the

**Fig. 1.** Receiver operating characteristic curve (ROC) showing the sensitivity and specificity of the concentration cut offs of the *E. ivorensis* leaf extract on *L. enriettii* promastigote inhibition.**Table 2.** Time-dependent inhibition of *L. enriettii* promastigotes treated with the optimal concentration of $62.3 \mu\text{g ml}^{-1}$ of the *E. ivorensis* leaf extract

Time hr^{-1}	% inhibition per time (cell ml^{-1})		
	mean \pm SE	95% CI	Huber's estimator
12	12.73 \pm 3.69	3.25–22.21	12.18
24	19.05 \pm 5.63	3.81–34.28	16.79
48	34.13 \pm 9.37	10.04–58.23	31.49
72	44.67 \pm 11.87	14.16–75.17	40.58

S.E, Standard error of the mean; CI, confidence interval.

already challenging treatment and clinical management of the disease [19]. Current treatment efficacy varies substantially from species or geographical isolates [20, 21].

A non-human pathogenic *Leishmania* parasite, *L. enriettii* complex, which causes cutaneous leishmaniasis in guinea pigs (*Cavia porcellus*), red kangaroo (*Macropus rufus*), northern wallaroos (*Macropus robustus woodwardii*), black wallaroos (*Macropus bernardus*) and agile wallabies (*Macropus agilis*), recently has been isolated from human infections in Martinique Island, Thailand and Ghana [22–24]. The ability of the *L. enriettii* complex, a causative agent of cutaneous leishmaniasis (CL) to infect a wide range of vertebrate hosts suggests its high plasticity [25, 26]. However, many aspects of this *Leishmania* parasite including its biology, vectorial transmission and epidemiology are still unknown.

In 2015, this Ghanaian *Leishmania* isolate was identified to belong to the *L. enriettii* complex [24]. Recent research has intimated the possibility of adapting the Ghanaian isolate into a laboratory guinea-pig model to study the infective amastigote stage.

This study was therefore conducted to identify the MIC of *E. ivorensis* leaf extract required to obtain ideal leishmanicidal activity against the promastigote stage of human pathogenic *L. enriettii* complex isolates from Ghana. We show that the minimum concentration of the leaf extract of *E. ivorensis* for ideal leishmanicidal activity is $62.5 \mu\text{g ml}^{-1}$.

METHODS

Plant extracts

E. ivorensis (Fabaceae) leaves were collected from Cape Coast in the Central Region of Ghana between April 2012 and August 2013. The plants were authenticated by Botanists in the School of Biological Sciences. The leaves of *E. ivorensis* [BHM/Eryth/017R/2014], were crude extracted using a previously described method [12]. The samples were pulverized and crude compounds extracted using 70% ethanol in round bottom flasks for 3 continuous days. The ethanol was decanted from the extracts and further filtered using Whatman filter paper. The filtrates were concentrated to a semi-solid extract




Fig. 2. Inhibition of *L. enriettii* promastigote at $62.3\mu\text{g ml}^{-1}$ of *E. ivorense* leaf extract. (a) Box plot showing inhibition of *L. enriettii* promastigotes per time of the *E. ivorense* leaf extract treatment. (b) Control chart for *L. enriettii* promastigote inhibition per time of the *E. ivorense* leaf extract treatment.

with a rotary evaporator regulated at 60°C and completely dried using activated silica gels. The phytochemical analysis was adapted from Anning's thesis work [12], which showed the presence of alkaloids, flavonoids, saponins, tannins, steroids and anthraquinone. Glycosides and triterpenoids were not detected in the extract.

Extract preparation

A $500\mu\text{g ml}^{-1}$ stock of ethanolic leaves extract of *E. ivorense* was dissolved in 1% DMSO in M199 complete solution. A serial dilution of 250, 125, 62.5, 31.3 and $15.6\mu\text{g ml}^{-1}$ of the stock was made with M199 medium. A $2.5\mu\text{g ml}^{-1}$ of

amphotericin B was also prepared as a positive control drug. The preparation was stored at 4°C for 7 days [12, 13].

Leishmania parasites' culture

Cryopreserved *Leishmania* promastigotes of Ghanaian *Leishmania* isolate and *L. donovani* were rapidly thawed and cultured in M199 complete medium containing 10% of foetal bovine serum (FBS), 1% basal medium Eagle (BME), vitamins, and 0.25% gentamicin with 1% of urine and cultured at 25°C in an incubator [27]. The motility of the promastigotes was monitored daily for 72 h under the X40 inverted microscope and its viability determined by staining the live

parasites with the trypan blue dye for differential count and exclusion of dead cells from the live-cell parasites [28]. The promastigotes counts were made daily by estimating the number of parasites using a haemocytometer. Large cultures of the promastigotes were made for extract sensitivity tests on the parasites.

Extract sensitivity test and trypan blue quantification assay

The number of promastigotes of *Leishmania* isolates from Ghana and *L. donovani* were adjusted to 1×10^6 cell ml^{-1} and seeded into 96-well plates in triplicates for each of the serialised concentration (500, 250, 125, 62.5, 31.3 and $15.6 \mu\text{g ml}^{-1}$) of the extracts. In total, $2.5 \mu\text{g ml}^{-1}$ of standard amphotericin B and 1% DMSO (dimethyl sulfoxide) were used as positive and negative drug controls, respectively. Parasites were cultured at 25°C for 24 h. The efficient extract concentration for promastigote growth inhibition was estimated using 0.4% trypan blue dye with 1:1 dilution of the cell suspension, incubated in a humid chamber for 10 min, followed cell counting by a haemocytometer and determination of viability [29, 30]. Promastigote inhibition by serially diluted concentrations of the extract was quantified by measuring the intensity of trypan blue by a spectrophotometer [31]. The $62.5 \mu\text{g ml}^{-1}$ threshold of the extract concentration showed to have the best sensitivity and specificity to inhibit the promastigote of the Ghanaian *Leishmania* isolate. Promastigote inhibition was measured at 12, 24, 48 and 72 h. To confirm $62.5 \mu\text{g ml}^{-1}$ as the best extract concentration for promastigote inhibition, we tested for 12 h inhibition.

For the trypan blue quantification assay, the extract-treated promastigotes were stained with 0.4% trypan blue solution at room temperature for 10 min followed by thorough but gentle washing three times with $200 \mu\text{l}$ of culture medium to remove the stain solution and background by rocking and centrifuging at 1000 r.p.m. for 3 min. Randomly, some of the samples were microscopically observed to check the ratio of dead to living promastigotes before lysing the samples with $200 \mu\text{l}$ of 1% sodium dodecyl sulfate (SDS) in a complete culture medium. To control the background trypan blue intensity, empty tubes were incubated with trypan blue and treated in a similar way to the test samples and used as a sham control. Also, samples from the log phase of promastigotes were also lysed and used as a control for viable promastigotes. A 72 h culture of *Leishmania* isolates in $2.5 \mu\text{g ml}^{-1}$ of amphotericin B, which kills more than 90% of promastigotes, were used as an inhibition control for extract inhibition. Samples were analysed spectrophotometrically at 590 nm using a microtitre plate reader (800TM TS absorbance reader, BioTeK instrument, USA). The mean absorbance values obtained were controlled for the background absorbance [31]. The promastigote inhibition by the extract was expressed as a percentage of live promastigotes, prepared at specific time points of 12, 24, 48 and 72 h.

Data analysis

The data obtained were recorded using a Microsoft Excel 2010 worksheet and analysed with SPSS version 16. The promastigote inhibition by the extract and amphotericin B were quantified using a light microscope and spectrophotometer. The results were expressed as the percentage mean inhibition of the promastigotes. The effective extract concentration of *E. ivorensis* was estimated using concentration cut-off value statistics and the receiver operating characteristic (ROC) curve. Time- and concentration-dependent inhibition of the concentration thresholds of the extract were calculated using $\text{mean} \pm \text{SE}$, Huber's estimator and a control chart. Monte Carlo chi-square was used to compare inhibition activity against the MIC of *E. ivorensis* extract and amphotericin B against *L. donovani* and *L. enriettii* complex isolates.

RESULTS

Selection of threshold concentration of ethanolic leaf extract of *E. ivorensis* for optimum inhibition of the promastigote stage of *L. enriettii* complex isolates from Ghana

The threshold of *E. ivorensis* extract to inhibit the promastigote stage of the *L. enriettii* complex isolate was selected by exposing the promastigotes to a serial dilution of the extract (15.6, 31.2, 62.3, 125, 250 and $500 \mu\text{g ml}^{-1}$) for 24 h. The inhibition of the promastigotes was measured after 24 h of post-extract exposure. The viable promastigote cells were detected by staining with trypan blue stains and absorbance measured at 590 nm using a spectrophotometer [32]. The MIC for the serially diluted extracts against the promastigote *L. enriettii* complex isolates were determined using concentration cut-off statistics. The results showed that concentration between $>53 \mu\text{g ml}^{-1}$ (% sensitivity of 66.67, 95% CI [22.28–95.67] with % specificity of 33.33, 95% CI [4.327–77.72]; likelihood ratio of 1.000) and $>64.5 \mu\text{g ml}^{-1}$ (% sensitivity of 66.67, 95% CI [22.28–95.6] with % specificity of 50.00, 95% CI [11.81–88.19]; likelihood ratio of 1.333) had the MIC of the ethanolic leaf extract of *E. ivorensis* required to significantly inhibit the growth of the promastigote *L. enriettii* complex isolate from Ghana. Although extract concentration $>215.5 \mu\text{g ml}^{-1}$ showed 100% specificity, 95% CI (54.07–100.0), it recorded the lowest sensitivity of 16.67%, 95% CI (0.4211–64.12). Again, concentration $>15 \mu\text{g ml}^{-1}$ recorded 100% sensitivity, 95% CI (54.07–100.0) with lowest specificity of 16.67%, 95% CI (0.4211–64.12) with a likelihood ratio of 1.200 (Table 1). Similarly, the area under the curve of ethanolic leaf extract of *E. ivorensis* with a concentration between $>53 \mu\text{g ml}^{-1}$ and $>64.5 \mu\text{g ml}^{-1}$ showed MIC with 50% sensitivity for inhibiting the growth of the promastigote stage of *L. enriettii* complex isolates from Ghana in *in vitro* culture (Fig. 1). This indicates that the MIC of the *E. ivorensis* extract that can significantly inhibit the *L. enriettii* complex isolate upon exposure is $62.3 \mu\text{g ml}^{-1}$.

Time-dependent growth inhibitory activity of 62.3 µg ml⁻¹ of ethanolic leaf extract of *E. ivorensis* against the promastigote stage of the *L. enriettii* complex isolate

The effectiveness of 62.3 µg ml⁻¹ of *E. ivorensis* extract to inhibit the growth of *L. enriettii* complex isolate promastigotes was tested by exposing the parasites to the extract and the inhibitory effect measured at 12, 24, 48 and 72 h. The highest promastigote inhibition with 62.3 µg ml⁻¹ was observed at 72 h with the mean inhibition of 44.67% (standard error of the mean=11.83%), 95% CI (14.16–75.17%); Huber's estimator=40.58 while the lowest promastigote inhibition was observed at 12 h post-treatment (mean inhibition=12.73%; standard error of the mean=3.69%; 95% CI [3.25–22.21%] and Huber's estimator=12.18) (Table 2). The effectiveness of 62.3 µg ml⁻¹ of the extract to inhibit the promastigote stage of the *L. enriettii* complex isolate was assessed using a univariate control chart. The result confirmed the time-dependent inhibitory activity of 62.3 µg ml⁻¹ of the extract against the promastigotes of the *L. enriettii* complex isolate. The lowest inhibition was observed at 12 h post-treatment and the highest promastigote inhibition was observed at 72 h, as shown in the box plot (Fig. 2a). The quality of promastigote inhibition by 62.3 µg ml⁻¹ over time showed that promastigote inhibition falls between the upper control limit (UCL) of 50.8054 and lower control limit (LCL) of 4.4863 with an average of 27.6458 (Fig. 2b). This indicates that *E. ivorensis* extract concentration of 62.3 µg ml⁻¹ falls into the desired sensitivity and specificity obtained from the concentration cut-off values (Table 1) and has an inhibitory activity against the promastigote stage *L. enriettii* complex isolate. Again, high concentrations of *E. ivorensis* extract showed a strong inhibitory effect on promastigotes of the *L. enriettii* complex isolate at 125 (mean inhibition=30.93%; standard error of the mean=8.78%; 95% CI [2.99–58.85%] and Huber's estimator=29.11), 250 and 500 µg ml⁻¹ (mean inhibition=56.43%; standard error of the mean=13.65%; 95% CI [12.99–99.86%] and Huber's estimator=55.65) at 24 h post-treatment (Table 3). Similarly, the univariate control chart also showed that the higher the concentration, the greater the

Table 3. Inhibition of *L. enriettii* promastigotes treated with serially diluted concentration of the *E. ivorensis* leaf extract

Conc. µg ml ⁻¹	% inhibition per conc. (cell ml ⁻¹)		
	Mean±SE	95% CI	Huber's estimator
15.6	8.50±3.65	-3.12–20.12	8.07
31.2	12.53±3.27	2.12–22.93	11.44
62.3	15.93±3.18	5.81–26.04	15.83
125	30.93±8.78	2.99–58.85	29.11
250	41.58±11.03	6.48–76.67	40.65
500	56.43±13.65	12.99–99.86	55.65

S.E, Standard error of the mean; CI, confidence interval.

inhibition means of the promastigotes. However, 500 µg ml⁻¹ of *E. ivorensis* extract crossed the UCL of 50.912 suggesting potential toxicity (Fig. 3a, b). This is in agreement with the concentration cut-off analysis, which showed high percentages of specificity but low percentages of sensitivity to *L. enriettii* isolate promastigote inhibition (Table 1).

The effect of *E. ivorensis* leaf extract was tested with a standard leishmanicidal drug amphotericin B (2.5 µg ml⁻¹) after 72 h post-treatment using *L. donovani* as a control parasite. The result showed that there was no significant inhibitory effect between the *E. ivorensis* extract and amphotericin B on *L. donovani* ($\chi^2=1.012$, Monte Carlo statistics=0.356, 95% CI [0.344–0.369]). However, *E. ivorensis* extract significantly inhibited the promastigotes of the *L. enriettii* isolate from Ghana comparable to amphotericin B ($\chi^2=15.934$, Monte Carlo statistics=0.00, 95% CI [0.00–0.00]) (Table 4). This suggests that 62.3 µg ml⁻¹ of *E. ivorensis* leaf extract can be used as the best concentration for the treatment of *L. enriettii* complex isolates from Ghana.

DISCUSSION

The isolation of the *L. enriettii* complex isotype in the Volta Region of Ghana is an indication of the expansion, emergence and adaptation of zoonotic leishmaniasis [24, 33, 34]. This isolate causes cutaneous leishmaniasis [24]. Understanding of the biology of this new isolate is important for efficient treatment and eradication of cutaneous leishmaniasis from Ghana. The infectivity of the *L. enriettii* complex isolate requires the understanding of the amastigote stage of the parasite. Current research findings indicate that wild guinea pigs are the host of the *L. enriettii* complex, which suggests that the isolate can be adapted into a guinea-pig model. As part of the preparatory laboratory adaptation of the isolate, the MIC of crude leaf extracts of *E. ivorensis* with leishmanicidal activity was determined. The extract of *E. ivorensis* is affordable, accessible and it has shown efficient antileishmanial activity against the promastigote stage of this *L. enriettii* complex isolate [12, 13]. The extracts of *E. ivorensis* have been shown to have lower side effects on the host organisms [35, 36].

Identification of a potential therapeutic agent for the treatment of extensive hyper-immune stimulation underlying cutaneous leishmaniasis such as diffuse CL or Post kala-azar dermal leishmaniasis (PKDL) that result in disfiguring and disability is essential for the treatment of *L. enriettii* complex infection [37, 38]. These CL-mediated immune dysfunctions make *E. ivorensis* extracts a therapeutic agent of choice aside its leishmanicidal activities against the promastigote stage of the *L. enriettii* complex isolate [39, 40]. The anti-inflammatory, antiallergic, wound-healing activities of *E. ivorensis* makes it a potential desired drug candidate for the topical treatment of cutaneous leishmaniasis [41].

Here we show that 62.3 µg ml⁻¹ as the MIC of *E. ivorensis* leaf extract has the best specificity and sensitivity for its leishmanicidal effects against the promastigote stage of the *L. enriettii* complex isolate from Ghana. Many antimonial drugs




Fig. 3. Inhibition of *L. enriettii* promastigotes per the serially diluted concentration of the *E. ivorense* leaf extract treatment. (a) Box plot showing promastigote inhibition per the concentration of *E. ivorense* leaf extract. (b) Control chart for promastigote inhibition per concentration of the *E. ivorense* leaf extract.

eliminate *Leishmania* parasites through immunomodulation mechanisms [42]. For instance, miltefosine activates host pro-inflammatory chemokines such as IFN- γ , TNF- α and IL-12 while upregulating CCL2, CXCL-9 and CXCL-10 [43–46]. The immune regulatory activities of *E. ivorense* extract underlying its anti-inflammatory, antiallergic and wound-healing abilities could facilitate rapid treatment of cutaneous leishmaniasis [39, 41]. Although the mechanisms underlying the anti-inflammatory, antiallergic and the wound-healing abilities of *E. ivorense* are not well understood, yet the immune

regulation coupled with its leishmanicidal ability can be capitalized on for the treatment of cutaneous leishmaniasis.

The adaptation of *L. enriettii* complex isolates from Ghana into a guinea-pig model is essential for the study of the biology of this geographical *Leishmania* isolate. This is important because of the variation in drug sensitivity and efficacy among species and geographical *Leishmania* isolates [47]. The genetic composition and biochemical characteristics among the species had been the cause of variation in drug sensitivity

Table 4. Comparable inhibitory effect of the optimized concentration of the *E. ivorensis* leaf extract and amphotericin B against the *L. enriettii* complex isolate from Ghana and *L. donovani*

	Cell ml ⁻¹ (% inhibition of promastigotes)			
	<i>E. ivorensis</i>	Amphotericin B	x ²	Monte Carlo (99% CI)
<i>L. donovani</i>	77 (12.38)	90 (24.67)	1.012	0.356 (0.344–0.369)
<i>L. enriettii</i> complex	174 (36.42)	258 (42.81)	15.934**	0.00 (0.00–0.00)

* Significant ($P < 0.05$); ** Significant ($P < 0.01$); *** Highly significant ($P < 0.001$).

to different species of *Leishmania* [48]. For instance, *Leishmania* isolates from Sudan and Ethiopia show 14.3 and 93.1 % cure rate by paromomycin treatment; dithiocarbamates and its structurally related compounds have good efficacy against intracellular *L. donovani* and *L. major* but are ineffective against intracellular *L. amazonensis*, whereas miltefosine exhibits species-specific susceptibility [49, 50].

In conclusion, 62.5 µg ml⁻¹ of *E. ivorensis* leaf extract is the MIC with the best leishmanicidal activities against the promastigote stage of the *L. enriettii* complex isolate from Ghana. This suggests that we can capitalize on its immunomodulatory effects against inflammation, and wound-healing effects as a drug candidate of choice for topical treatment of cutaneous leishmaniasis caused by the *L. enriettii* complex isolate.

Funding information

This work was funded by the authors and supported by the Department of Biomedical Sciences, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Ghana.

Acknowledgements

We thank the staff of the Herbarium of the School of Biological Sciences, University of Cape Coast and the Department of Pharmacognosy, Kwame Nkrumah University of Science and Technology for donating *E. ivorensis* used for this study.

Conflict of interest

The authors declare that there are no conflicts of interest.

Author's contribution

All authors contributed equally.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Reference

- Boamong JN, Ameyaw EO, Aboagye B, Asare K, Kyei S et al. The Curative and Prophylactic Effects of Xylopic Acid on *Plasmodium berghei* Infection in Mice. *J Parasitol Res* 2013;2013:1–7.
- Johnson NB, Ameyaw EO, Kyei S, Aboagye B, Asare K et al. In vivo antimalarial activity of stem bark extracts of *Plumeria alba* against *Plasmodium berghei* in imprinting control region mice. *Reports in parasitology* 2013;3:19.
- Yun C-H, Estrada A, Van Kessel A, Park B-C, Laarveld B. Beta-Glucan, extracted from oat, enhances disease resistance against bacterial and parasitic infections. *FEMS Immunol Med Microbiol* 2003;35:67–75.

- Patra MC, Choi S. Recent progress in the development of Toll-like receptor (TLR) antagonists. *Expert Opin Ther Pat* 2016;26:719–730.
- Oliveira AB, Dolabela MF, Braga FC, Jácome RLRP, Varotti FP et al. Plant-Derived antimalarial agents: new leads and efficient phyto-medicines. Part I. alkaloids. *An. Acad. Bras. Ciênc.* 2009;81:715–740.
- Saxena S, Pant N, Jain DC, Bhakuni RS. Antimalarial agents from plant sources. *Current science* 2003;85:1314–1329.
- Ogboru RO, Akideno LO, Owoeye EA. Chemical composition and medicinal potentials of the bark of *Erythrophleum ivorensis* a. *Chev.*
- Adu-Amoah L. Antimicrobial and toxicity studies of erythrophleum *ivorensis* (Leguminosae) and *parquetina nigrescens* (Asclepiadaceae). Doctoral dissertation; 2014.
- Kyere-Davies G, Agyare C, Boakye YD, Suzuki BM, Caffrey CR. Effect of Phenotypic Screening of Extracts and Fractions of *Erythrophleum ivorensis* Leaf and Stem Bark on Immature and Adult Stages of *Schistosoma mansoni*. *J Parasitol Res* 2018;2018:1–7.
- Armah FA, Annan K, Mensah AY, Amponsah IK, Tocher DA et al. Erythroivorensin: a novel anti-inflammatory diterpene from the root-bark of *Erythrophleum ivorensis* (a CheV). *Fitoterapia* 2015;105:37–42.
- Laird SA. The management of forests for timber and non-wood forest products in central Africa. *Non-Wood Forest Products of Central Africa: Current Research Issues and Prospects for Conservation and Development*. Food and Agriculture Organization. Rome, Italy: of the United Nations; 1998. pp. 51–60.
- Anning AS. *In vitro anti leishmanial activity of some selected medicinal plants in Ghana* (Doctoral dissertation, University of Cape Coast).
- Armah FA, Amponsah IK, Mensah AY, Dickson RA, Steenkamp PA et al. Leishmanicidal activity of the root bark of *Erythrophleum ivorensis* (Fabaceae) and identification of some of its compounds by ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-QTOF-MS/MS). *J Ethnopharmacol* 2018;211:207–216.
- Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. *PLoS Negl Trop Dis* 2008;2:e313.
- Cavalli A, Bolognesi ML. Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against *Trypanosoma* and *Leishmania*. *J Med Chem* 2009;52:7339–7359.
- Prajapati VK, Pandey RK. Recent advances in the chemotherapy of visceral leishmaniasis. *In Drug design: Principles and applications*. Singapore: Springer; 2017. pp. 69–88.
- Pham TTH, Loiseau PM, Barratt G. Strategies for the design of orally bioavailable antileishmanial treatments. *Int J Pharm* 2013;454:539–552.
- Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. *Leishmaniasis: a review*. F1000. *Research* 2017;6.
- Webster JP, Gower CM, Knowles SCL, Molyneux DH, Fenton A. One health - an ecological and evolutionary framework for tackling neglected zoonotic diseases. *Evol Appl* 2016;9:313–333.
- Sundar S, Sinha PK, Rai M, Verma DK, Nawin K et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. *The Lancet* 2011;377:477–486.
- den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. *Clin Microbiol Infect* 2011;17:1471–1477.
- Paranaíba LF, Pinheiro LJ, Torrecilhas AC, Macedo DH, Menezes-Neto A et al. Muniz & Medina, 1948: A highly diverse parasite is here to stay. *PLoS pathogens* 2017;13:e1006303.
- Aronson NE, Joya CA. Cutaneous leishmaniasis: updates in diagnosis and management. *Infect Dis Clin North Am* 2019;33:101–117.
- Kwakye-Nuako G, Mosore M-T, Duplessis C, Bates MD, Pupilampu N et al. First isolation of a new species of *Leishmania* responsible for human cutaneous leishmaniasis in Ghana and classification in the *Leishmania enriettii* complex. *Int J Parasitol* 2015;45:679–684.

25. Schönian G, Lukeš J, Stark O, Cotton JA. Molecular evolution and phylogeny of Leishmania. In *Drug Resistance in Leishmania Parasites*. Springer, Cham; 2018. pp. 19–57.
26. Dvorak V, Shaw J, Volf P. Parasite Biology: the Vectors. In *the Leishmaniasis: Old Neglected Tropical Diseases*. Springer, Cham; 2018. pp. 31–77.
27. Islamuddin M, Sahal D, Afrin F. Apoptosis-Like death in Leishmania donovani promastigotes induced by eugenol-rich oil of Syzygium aromaticum. *J Med Microbiol* 2014;63:74–85.
28. Wenzel UA. Stage specific interactions of Leishmania major with host phagocytes. Doktorarbeit, research center Borstel, Leibniz-Center for medicine and biosciences, department of molecular infection biology. *Division of Microbial Interface Biology* 2009.
29. Doran TI, Herman R. Characterization of populations of promastigotes of *Leishmania donovani*. *J Protozool* 1981;28:345–350.
30. Ferreira TN, Pita-Pereira D, Costa SG, Brazil RP, Moraes CS et al. Transmission blocking sugar baits for the control of Leishmania development inside sand flies using environmentally friendly beta-glycosides and their aglycones. *Parasit Vectors* 2018;11:614.
31. Illien F, Rodriguez N, Amoura M, Joliot A, Palleria M et al. Quantitative fluorescence spectroscopy and flow cytometry analyses of cell-penetrating peptides internalization pathways: optimization, pitfalls, comparison with mass spectrometry quantification. *Sci Rep* 2016;6:36938.
32. Chowdhury KD, Sen G, Sarkar A, Biswas T. Role of endothelial dysfunction in modulating the plasma redox homeostasis in visceral leishmaniasis. *Biochimica et Biophysica Acta (BBA) - General Subjects* 2011;1810:652–665.
33. Villinski JT, Klena JD, Abbassy M, Hoel DF, Pupilampu N et al. Evidence for a new species of Leishmania associated with a focal disease outbreak in Ghana. *Diagn Microbiol Infect Dis* 2008;60:323–327.
34. Fryauff DJ, Hanafi HA, Klena JD, Hoel DF, Appawu M et al. Short report: ITS-1 DNA sequence confirmation of Leishmania major as a cause of cutaneous leishmaniasis from an outbreak focus in the HO district, southeastern Ghana. *Am J Trop Med Hyg* 2006;75:502–504.
35. Adu-Amoah L, Agyare C, Kisseih E, Ayande PG, Mensah KB. Toxicity assessment of *Erythrophleum ivorense* and *Parquetina nigrescens*. *Toxicol Rep* 2014;1:411–420.
36. Wakeel O, Umukoro S, Kolawole OT, Awe E, Ademowo O. Anti-convulsant and sedative activities of extracts of *Erythrophleum ivorense* stem bark in mice. *AJBPS* 2014;4:43.
37. McGwire BS, Satoskar AR. Leishmaniasis: clinical syndromes and treatment. *QJM* 2014;107:7–14.
38. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. *Expert Opin Pharmacother* 2015;16:237–252.
39. Loría-Cervera EN, Andrade-Narváez FJ. Animal models for the study of leishmaniasis immunology. *Revista do Instituto de Medicina Tropical de São Paulo* 2014;56:1–11.
40. Birnbaum R, Craft N. Innate immunity and Leishmania vaccination strategies. *Dermatol Clin* 2011;29:89–102.
41. Wakeel OK. Analgesic, anti-inflammatory and anti-convulsant activities of stem bark extract of *Erythrophleum ivorense* (a CheV) in rats and mice. Doctoral dissertation, University of Ibadan, Nigeria; 2014.
42. Chakravarty J, Sundar S. Drug resistance in leishmaniasis. *J Glob Infect Dis* 2010;2:167.
43. Ansari NA, Saluja S, Salotra P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. *Clin Immunol* 2006;119:339–345.
44. Nylén S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. *Trends Immunol* 2007;28:378–384.
45. Ashwin H, Seifert K, Forrester S, Brown N, MacDonald S et al. Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasis. *Wellcome Open Res* 2018;3:135.
46. Bhattacharya P, Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. *Rev Soc Bras Med Trop* 2013;46:128–134.
47. Fernández OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S et al. Miltefosine and antimonial drug susceptibility of *Leishmania Viannia* species and populations in regions of high transmission in Colombia. *PLoS Negl Trop Dis* 2014;8:e2871.
48. Adau V, Schnorbusch K, Zimic M, Gutiérrez A, Decuyper S et al. Comparison of gene expression patterns among *Leishmania braziliensis* clinical isolates showing a different *in vitro* susceptibility to pentavalent antimony. *Parasitology* 2011;138:183–193.
49. Gadisa E, Tsegaw T, Abera A, Elnaiem D-E, den Boer M et al. Eco-epidemiology of visceral leishmaniasis in Ethiopia. *Parasit Vectors* 2015;8:381.
50. Elmahallawy EK, Agil A. Treatment of leishmaniasis: a review and assessment of recent research. *Curr Pharm Des* 2015;21:2259–2275.

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.